TABLE 4.

MIC distributions for antimicrobials against all CRE isolated from blood specimens in China during 2018–2019.

MIC (mg/L)	No.a	Percentages of isolates by MIC												MIC50	MIC90	MIC range
Antibiotic		0.03	0.06	0.125	0.25	0.5	1	2	4	8	16	32	64
CRKP (n = 511)
Tigecycline	511	0.98	1.57	9.59	33.86	22.31	25.64	4.89	0.78	0.39	0	0	0	0.5	1	0.03–8
Polymyxin B	511	0	0	0	4.11	57.73	20.94	11.35	2.15	0.98	1.76	0.98	0	0.5	–	0.25–32
Ceftazidime/avibactam	325	0	0.31	0.31	0	1.85	5.23	12.62	34.15	37.23	0.92	7.38	0	4	16	0.06–32
CREC (n = 83)
Tigecycline	83	4.82	4.82	15.66	61.45	4.82	6.02	2.41	0	0	0	0	0	0.25	0.5	0.03–2.41
Polymyxin B	83	0	0	0	7.23	53.01	21.69	15.66	2.41	0	0	0	0	0.5	2	0.25–4
Ceftazidime/avibactam	61	0	0	0	0	3.28	3.28	1.64	6.56	24.59	6.56	54.1	0	32	32	0.5–54.1
CRE species except CRKP and CREC (n = 59).
Tigecycline	52	0	0	8.93	55.36	23.21	8.93	3.57	0	0	0	0	0	0.25	1	0.125–2
Polymyxin B	56	0	0	0	6.67	28.33	41.67	13.33	1.67	3.33	0	5	0	1	2	0.25–32
Ceftazidime/avibactam	59	0	0	0	5.08	1.69	3.39	1.69	6.78	1.69	1.69	69.49	8.47	32	32	0.25–64

MIC, minimum inhibitory concentration; CRE, carbapenem-resistant Enterobacterales; MIC₅₀, 50% minimum inhibitory concentration; MIC₉₀, 90% minimum inhibitory concentration;

^aNo., number of isolates in which antibiotic sensitivity was tested; CRKP, carbapenem-resistant Klebsiella pneumoniae; CREC, carbapenem-resistant Escherichia coli.